Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 4/20 | 0.48 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | CCNC | P24863 | 4/20 | 0.43 |
| ▸ | CDK8 | P49336 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PASK | Q96RG2 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19902501 | 0.93 | PTGER3 (0.47) | KHKPTGER3ROCK2CCNCCDK8 | |
| SCHEMBL17452898 | 0.89 | ROCK2 (0.59) | KHKPTGER3ROCK2PDE4BCCNC | |
| SCHEMBL19902622 | 0.86 | MAPK14 (0.54) | KHKROCK2HPGDPLK1MAPK14 | |
| SCHEMBL19902707 | 0.83 | KDM5A (0.49) | ROCK2HPGDPLK1MAPK14ALDH1A1 | |
| SCHEMBL17452888 | 0.82 | ROCK2 (0.59) | KHKPTGER3ROCK2CCNCCDK8 | |
| SCHEMBL19902369 | 0.81 | ROCK2 (0.46) | ROCK2MAPK14 | |
| SCHEMBL19902708 | 0.80 | HPGD (0.48) | ROCK2HPGDALDH1A1KDM4E | |
| SCHEMBL19902605 | 0.80 | CCNC (0.55) | ROCK2CCNCCDK8 | |
| SCHEMBL19902620 | 0.80 | ROCK2 (0.40) | ROCK2CCNCCDK8MAPK14ALDH1A1 | |
| SCHEMBL19902593 | 0.79 | USP30 (0.54) | ROCK2CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | KHK 2573/4885PTGER3 105/4885ROCK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.